Display options
Cite
Marrero I, Ware R, Kumar V. Type II NKT Cells in Inflammation, Autoimmunity, Microbial Immunity, and Cancer. Front Immunol. 2015;6:316doi: 10.3389/fimmu.2015.00316.
Marrero, I., Ware, R., & Kumar, V. (2015). Type II NKT Cells in Inflammation, Autoimmunity, Microbial Immunity, and Cancer. Frontiers in immunology, 6316. https://doi.org/10.3389/fimmu.2015.00316
Marrero, Idania, et al. "Type II NKT Cells in Inflammation, Autoimmunity, Microbial Immunity, and Cancer." Frontiers in immunology vol. 6 (2015): 316. doi: https://doi.org/10.3389/fimmu.2015.00316
Marrero I, Ware R, Kumar V. Type II NKT Cells in Inflammation, Autoimmunity, Microbial Immunity, and Cancer. Front Immunol. 2015 Jun 17;6:316. doi: 10.3389/fimmu.2015.00316. eCollection 2015. PMID: 26136748; PMCID: PMC4470258.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2015 Jun 17;6:316. doi: 10.3389/fimmu.2015.00316. eCollection 2015.

Type II NKT Cells in Inflammation, Autoimmunity, Microbial Immunity, and Cancer.

Frontiers in immunology

Idania Marrero, Randle Ware, Vipin Kumar

Affiliations

  1. Laboratory of Immune Regulation, Department of Medicine, University of California San Diego , La Jolla, CA , USA.

PMID: 26136748 PMCID: PMC4470258 DOI: 10.3389/fimmu.2015.00316

Abstract

Natural killer T cells (NKT) recognize self and microbial lipid antigens presented by non-polymorphic CD1d molecules. Two major NKT cell subsets, type I and II, express different types of antigen receptors (TCR) with distinct mode of CD1d/lipid recognition. Though type II NKT cells are less frequent in mice and difficult to study, they are predominant in human. One of the major subsets of type II NKT cells reactive to the self-glycolipid sulfatide is the best characterized and has been shown to induce a dominant immune regulatory mechanism that controls inflammation in autoimmunity and in anti-cancer immunity. Recently, type II NKT cells reactive to other self-glycolipids and phospholipids have been identified suggesting both promiscuous and specific TCR recognition in microbial immunity as well. Since the CD1d pathway is highly conserved, a detailed understanding of the biology and function of type II NKT cells as well as their interplay with type I NKT cells or other innate and adaptive T cells will have major implications for potential novel interventions in inflammatory and autoimmune diseases, microbial immunity, and cancer.

Keywords: CD1d; autoimmunity; cancer; inflammation; innate immunity; lipids; neutrophils; sulfatide

References

  1. Nat Immunol. 2010 Mar;11(3):197-206 - PubMed
  2. Nat Immunol. 2012 Sep;13(9):857-63 - PubMed
  3. Inflamm Bowel Dis. 2013 May;19(6):1330-8 - PubMed
  4. J Immunol. 2013 Dec 1;191(11):5349-53 - PubMed
  5. J Immunol. 2012 Apr 1;188(7):3138-49 - PubMed
  6. Cell Mol Immunol. 2016 Mar;13(2):206-16 - PubMed
  7. Gastroenterology. 2011 Feb;140(2):646-55 - PubMed
  8. Gut. 2009 Jul;58(7):974-82 - PubMed
  9. Curr Opin Immunol. 2013 Dec;25(6):690-6 - PubMed
  10. Nat Immunol. 2012 Sep;13(9):851-6 - PubMed
  11. J Exp Med. 2004 Apr 5;199(7):947-57 - PubMed
  12. Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1827-32 - PubMed
  13. J Clin Invest. 2004 May;113(10):1490-7 - PubMed
  14. J Endocrinol. 2014 Nov;223(2):R41-8 - PubMed
  15. Hepatology. 2015 Apr;61(4):1357-69 - PubMed
  16. Front Immunol. 2014 Oct 28;5:543 - PubMed
  17. Eur J Gastroenterol Hepatol. 2009 Jun;21(6):673-80 - PubMed
  18. J Exp Med. 2011 Jun 6;208(6):1163-77 - PubMed
  19. Nat Rev Microbiol. 2007 Jun;5(6):405-17 - PubMed
  20. J Cell Physiol. 2009 Feb;218(2):246-50 - PubMed
  21. Immunology. 2014 Jul;142(3):321-36 - PubMed
  22. J Immunol. 2014 Aug 1;193(3):1035-46 - PubMed
  23. PLoS One. 2011;6(6):e20702 - PubMed
  24. Annu Rev Immunol. 2004;22:817-90 - PubMed
  25. J Immunol. 2013 Mar 1;190(5):1948-60 - PubMed
  26. Eur J Immunol. 2012 Nov;42(11):2851-60 - PubMed
  27. J Immunol. 2014 Jun 15;192(12):5490-8 - PubMed
  28. Immunol Cell Biol. 2014 Aug;92(7):578-90 - PubMed
  29. J Stem Cells. 2010;5(1):33-42 - PubMed
  30. J Clin Invest. 2007 Aug;117(8):2302-12 - PubMed
  31. J Immunol. 2007 Oct 15;179(8):5126-36 - PubMed
  32. Neurochem Res. 2007 Feb;32(2):257-62 - PubMed
  33. Nat Med. 2012 Jul;18(7):1060-8 - PubMed
  34. World J Gastroenterol. 2011 Apr 7;17(13):1725-31 - PubMed
  35. J Exp Med. 2001 Apr 16;193(8):893-904 - PubMed
  36. J Immunol. 2014 Nov 1;193(9):4580-9 - PubMed
  37. Cancer Res. 2013 Mar 1;73(5):1514-23 - PubMed
  38. Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2674-9 - PubMed
  39. Infect Immun. 2005 Jan;73(1):181-92 - PubMed
  40. Scand J Immunol. 2012 Sep;76(3):246-55 - PubMed
  41. Blood. 2008 Jun 15;111(12):5637-45 - PubMed
  42. Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10984-9 - PubMed
  43. Nat Rev Immunol. 2013 Feb;13(2):101-17 - PubMed
  44. Curr Opin Immunol. 2009 Aug;21(4):391-6 - PubMed
  45. Blood. 2008 Aug 15;112(4):1308-16 - PubMed
  46. J Infect Chemother. 2013 Aug;19(4):560-70 - PubMed
  47. J Clin Invest. 2004 Nov;114(10):1379-88 - PubMed
  48. PLoS One. 2012;7(5):e37771 - PubMed
  49. Blood. 2015 Feb 19;125(8):1256-71 - PubMed
  50. Science. 2011 Apr 8;332(6026):243-7 - PubMed
  51. PLoS One. 2010 May 24;5(5):e10800 - PubMed
  52. Annu Rev Immunol. 2007;25:297-336 - PubMed
  53. J Exp Med. 1993 Jan 1;177(1):57-68 - PubMed
  54. J Am Soc Nephrol. 2011 Jul;22(7):1305-14 - PubMed
  55. Infect Immun. 2013 Apr;81(4):1114-20 - PubMed
  56. Gastroenterology. 2012 Feb;142(2):326-34.e1-2 - PubMed
  57. J Immunol. 2008 Mar 1;180(5):2942-50 - PubMed
  58. Hepatology. 2010 Jun;51(6):1998-2007 - PubMed
  59. J Viral Hepat. 2013 Aug;20(8):556-65 - PubMed
  60. J Hepatol. 2013 Sep;59(3):618-20 - PubMed
  61. Gut. 2014 Nov;63(11):1728-36 - PubMed
  62. Trends Immunol. 2007 Nov;28(11):491-6 - PubMed
  63. J Immunol. 2006 Feb 15;176(4):2476-85 - PubMed

Publication Types

Grant support